CD274 and glioma: Although the above combination strategies in recurrent glioma were not satisfying, posttreatment analysis revealed therapeutic benefit correlates to indexes such as PD-L1 expression level, baseline steroid use, peripheral lymphocyte counts and gene expression profile, suggesting novel combination regimes and patient selection [9,35].